“Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis” (2020) SKIN The Journal of Cutaneous Medicine, 4(5), p. s43. doi:10.25251/skin.4.supp.43.